Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Understanding Leukaemia and Related Cancers

May 1, 2000
By Tariq I. Mughal, MB, MD, MRCP, FACP
Mary Cianfrocca, DO
Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a

 Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a valuable guide to the diagnosis and treatment of leukemia. The authors note that the book is intended for a varied audience, but I believe that it will be most useful to patients and family members who seek a better understanding of the disease and its implications.

The book consists of eight chapters, the first three of which attempt to provide readers with the scientific background that will help them gain a better understanding of the disease process. The authors have done an excellent job of explaining complicated medical information in relatively easy-to-understand language, and the well-chosen illustrations will likely add to the reader’s comprehension.

The prevalence of leukemia, as well as the possible etiologies for its development, are discussed. Many patients fear that they may have done something to cause their cancer, and the authors go to some length to try to dispel these concerns. They also provide a valuable resource in Appendix 1—a list of many active support organizations in the United Kingdom, the United States, and Spain.

The remaining chapters describe the diagnosis and treatment of the various types of leukemia. Clear, simple language is used to explain the usual work-up that is performed on the leukemia patient, as well as the rationale behind various procedures.

The potential benefits and toxicities of chemotherapy and radiation are discussed, and a separate chapter on bone marrow transplantation is also included. The authors remember to include toxicities that occur with certain therapies, such as red urine with daunorubicin (Cerubidine), that are not dangerous but that, nonetheless, may be frightening to the unprepared patient.

The authors also address the importance of patient participation in clinical trials. They make the important point that 90% of children in the United Kingdom with acute lymphoblastic leukemia—a disease in which tremendous advances have been made—are entered into clinical trials.

Although the chapter on leukemia therapy is well written, it contains a few inaccuracies. For example, the section on the treatment of hairy-cell leukemia is outdated: Treatment with interferon is emphasized, and 2-chlorodeoxyadenosine (cladribine [Leustatin]) is mentioned only briefly. Also, the authors state that high-dose cytarabine is used only occasionally when, in fact, it has now become the standard consolidation therapy for many patients with acute myeloid leukemia.

The book’s final chapter ends on a hopeful note by discussing future therapeutic prospects. Targeted therapy, such as gene therapy, is described, as well as some of the controversies surrounding bone marrow transplantation.

Any book that informs patients is always a valuable resource. Despite its few shortcomings, Understanding Leukaemia and Related Cancers provides patients and their families with much of the information that they will need for proper decision-making throughout the course of their disease. It also manages to present this complicated information in a simple, nonthreatening manner. Patients will likely find this book to be most useful as a starting point for further discussion with their physicians.

Articles in this issue

Medicare Rethinking Its Policy on Self-Injectables
Home Counseling Program for Women With Lung Cancer to Be Studied
New Indication Sought for Bicalutamide
Approval of Antibody-Targeted Chemotherapy Recommended
NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned
First Comparison of Anastrozole vs Tamoxifen
Prolonged Androgen Blockade May Boost Survival in Advanced Prostate Cancer
FDA Approves Irinotecan as First-Line Therapy for Colorectal Cancer
Understanding Leukaemia and Related Cancers
Bill Will Allow Doctors to Negotiate Jointly With HMOs
New Drug for Refractory Cutaneous T-Cell Lymphoma
New Clinical Trials Data Bank
Exisulind Shows Positive Results in the Prevention of Precancerous Colon Polyps
Commentary (Hewitt): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Commentary (Carr/Goudas): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Roman Fabbricatore
June 26th 2025
Article

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Roman Fabbricatore
June 26th 2025
Article

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.